Tag: Zepbound

Obesity Crisis Meets Policy Standstill as Trump Halts Medicare Expansion

Ester Adams
Medicare’s role in weight-loss drug coverage

Trump Administration Reverses Plans to Expand Medicare Coverage for Obesity Drugs The Trump administration has officially halted a Biden-era initiative that aimed to extend Medicare and Medicaid coverage to include obesity drugs, a move set to impact millions of Americans coping with obesity, disproportionately affecting seniors and lower-income groups. While supporters saw the proposed expansion as a progressive step towards tackling one of the nation’s most pressing health challenges, critics have raised concerns over the potential cost burden. Below, we untangle the implications of this decision, exploring its economic, medical,…

Read More

Government vs. Private: Who’s Really Paying for Your Weight-Loss Meds?

Logan B.
Weight-Loss Meds

In recent years, weight-loss meds like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have gained significant attention in the United States. These drugs belong to a class known as GLP-1 medications, primarily developed for diabetes management but increasingly used for weight loss. As demand for these treatments rises, understanding the landscape of insurance coverage for these drugs becomes crucial for consumers. Weight-Loss Meds Insurance Coverage Overview Insurance coverage for GLP-1 weight-loss drugs is complex and varies significantly across different plans. While government-funded programs like Medicaid and those covering federal, state,…

Read More